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Is shoulder involvement in clinically suspect
arthralgia an early feature of rheumatoid arthritis?
A longitudinal ultrasound study
Rheumatology key message
. Subclinical tenosynovitis of the biceps tendon is not
an early feature of RA in clinically suspect arthralgia
patients.
Sir, Multiple studies have demonstrated that shoulder
complaints are frequent in RA [1, 2]. Recently, it has
been shown that shoulder involvement is predictive of
RA development in patients with undifferentiated arthritis
and its value is comparable with that of small joint invol-
vement [3]. The phase of clinically suspect arthralgia pre-
cedes the phase of clinically apparent arthritis. In this
phase, subclinical tenosynovitis in small hand joints is
associated with developing RA [4]. Given the similarities
in predictive values between the shoulder and small joints
in undifferentiated arthritis, and the predictive value of
tenosynovitis in clinically suspect arthralgia, we hypothe-
sized that tenosynovitis of the bicep tendon visualized by
US is also associated with developing inflammatory arthri-
tis (IA) in clinically suspect arthralgia patients. We exam-
ined the biceps tendon, since this is the only tendon of the
shoulder that is enclosed by a synovial sheath as it passes
through the bicipital groove (Fig. 1AC) [5].
To answer our research question we used data from the
SONAR study, sonographic evaluation of hands,
shoulders and feet in patients presenting with inflamma-
tory arthralgia, to identify subclinical arthritis. This was a
multicentre observational cohort study. In this study, US
of both shoulders was made at baseline. US abnormalities
of the biceps tendon [1], the glenohumeral joint [2] and the
subdeltoid bursa [3] were assessed for tenosynovitis,
arthritis and bursitis. Thereafter, patients were followed
for the course of 1 year (with 6-monthly visits) for the
development of clinically apparent IA, which was verified
by the treating physician. The medical ethics committee of
Erasmus University Medical Center (Erasmus MC),
Rotterdam, The Netherlands approved the study (MEC-
2010353). Furthermore, the study was assessed for fea-
sibility by the local ethical bodies of the other two partici-
pating hospitals (Maasstad Hospital and Vlietland
Hospital). All patients gave written informed consent
before inclusion according to the Declaration of Helsinki.
Student’s t test and the MannWhitney test were used
to compare baseline values. US abnormalities between
groups were compared using a 2 test. A detailed
description of the cohort, US protocol, and statistics are
presented in the Supplementary Material, Methods sec-
tion, available at Rheumatology online.
A flowchart is presented as supplementary material,
available at Rheumatology online. No significant differ-
ences in baseline characteristics were found between
included and excluded patients (Supplementary Table
S1, available at Rheumatology online). Of the participants,
140 patients (82%) were female, the mean age was
45 years and the median symptom duration was
30 weeks (Fig. 1D). After 1 year, 37 patients (22%) had
developed IA and, of those patients, 17 (46%) fulfilled
the 2010 criteria for RA (Supplementary Table S2, avail-
able at Rheumatology online). The remaining 20 patients
were diagnosed with: undifferentiated arthritis (80%), OA
(15%) and PsA (5%). Shoulder pain was infrequent (5%)
and only observed in the non-IA group. ACPA positivity
was associated with IA development [odds ratio (OR)
3.14, 95% confidence interval 1.307.57, P = 0.0087]
(Fig. 1D).
Although shoulder pain was infrequent, we did find US
shoulder abnormalities in 50 patients (29%, Fig. 1D). None
were predictive for IA development. Subclinical tenosyno-
vitis of the biceps tendon was present in 15% and 11% of
clinically suspect arthralgia patients who, respectively, did
and did not develop IA (P = 0.48). Also, bilateral tenosyno-
vitis was evenly distributed between both groups (6% and
6%) (Supplementary Fig. S2, available at Rheumatology
online). A thickened biceps tendon and subdeltoid bursa
effusion were also not associated with IA development (P
= 0.19 and P = 0.094, respectively). Joint effusion was
absent (Fig. 1D). The subgroup analysis with RA as out-
come showed similar results (Supplementary Table S3,
available at Rheumatology online).
US abnormalities of the shoulder were less frequent in
our study than in other studies: biceps tenosynovitis
2344%, subdeltoid bursitis 1867% and effusion of the
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joint 2838% [6, 7]. However, these studies were per-
formed in established RA. It is plausible that these
patients had developed more abnormalities in the
shoulder joint over the years due to active inflammation.
On the other hand, US shoulder abnormalities are also
seen in healthy individuals and prevalences vary widely.
Iagnocco et al., for example, showed a prevalence of
28.9%, which is comparable with our overall prevalence
of 29% [8].
A strength of the current study was that US was
performed by two experienced ultrasonographers who
had received training prior to the start of the study. Also,
a standardized US protocol and scoring system was used
for scanning. In addition, analyses on primary and sec-
ondary outcomes provided similar results.
A limitation is that the number of patients that devel-
oped IA or RA and the frequency of US abnormalities
within this group were relatively low. Although this may
have harboured the risk of false-negative findings, there
was no tendency towards more US-detected
inflammation, even in the clinically suspect arthralgia
patients who progressed to IA. Therefore, further US stu-
dies on the shoulder in clinically suspect arthralgia would
not seem to be valuable.
In conclusion, subclinical tenosynovitis of the biceps
tendon, visualized with US, is not an early feature of RA
and is also not predictive of the development of RA.
Based on these results, standard US screening of the
shoulder is not necessary in clinically suspect arthralgia
patients for determining their risk of developing IA.
Funding: This work was supported by an investigator-
initiated grant from Pfizer bv. and funding from the
Dutch Arthritis Society.
Disclosure statement: The authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology online.
FIG. 1 Anatomical representation of the biceps tendon and baseline characteristics including US abnormalities
(A) Anatomy of the shoulder joint and the course of the biceps tendon through the bicipital groove. The letters indicate the
two perpendicular planes of the US probe for scanning the biceps tendon. (B) US of the transverse plane of the biceps
tendon. (C) US of the longitudinal plane of the biceps tendon. (D) Baseline characteristics and US abnormalities at
baseline in patients with clinically suspect arthralgia. Tub. Minus: tuberculum minus; Tub. majus: tuberculum majus; IA:
inflammatory arthritis; TJC44: tender joint count in 44 joints; SCJ44: swollen joint count in 44 joints. White asterisk
indicates biceps tendon.
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Association between celiac disease and systemic
lupus erythematosus: a Mendelian randomization
study
Rheumatology key message
. Mendelian randomization study suggested celiac
disease might be associated with the risk of SLE.
SIR, Celiac disease (CeD) is an autoimmune disease
characterized by immune-reaction to gluten by T lympho-
cytes with gastrointestinal manifestations in children.
Observationally, it has been reported that a variety of
other autoimmune diseases are associated with CeD [1].
Correspondingly, a few cases have been reported that
CeD precedes SLE [2]. In addition, >20% of patients
with CeD have anti-double stranded DNA antibody, rais-
ing the intriguing question of whether abnormal immune
responses in the gut play a role in systemic autoimmune
disease [3]. To examine the association between CeD and
SLE, I performed two-sample Mendelian randomization
(MR) using the inverse-variance weighted (IVW),
MR-Egger regression and weighted median methods. A
two-sample MR utilizes genetic variants as instrumental
variables (IVs) for assumption about causal impact of
exposure on outcome derived from different samples [4].
I used the publicly available datasets of genome-wide
association studies (GWASs) for CeD GWASs (12 041
cases and 12 228 controls) of the European population
as the exposure and SLE GWASs (1311 cases and 1783
controls) of the European population as the outcome [5,
6]. To improve inference, selection of genetic variants
associated with CeD as IVs was based on a linkage dis-
equilibrium R2 value of 0.001, clumping distance of 10 000
kb and P-value threshold of 5.00 108 (genome-wide
significance). Then, I examined the association between
single nucleotide polymorphisms (SNPs) and risk of SLE.
Finally, by combining the results acquired from of each
SNPs using MR analysis, I estimated the causal associa-
tion between CeD and risk of SLE. The effect size was
shown by the b-coefficient. I assessed heterogeneity
across SNPs by Cochran’s Q statistic. To explore whether
single SNPs drive causal association, I performed a leave-
one-out analysis. All MR analyses were performed in MR
Base platform (http://www.mrbase.org/; App version:
1.2.2 3a435d). The R script is in the supplementary mate-
rial, section ‘R Script’, available at Rheumatology online.
I obtained 11 SNPs as IVs from CeD GWASs
(Supplementary Table S1, available at Rheumatology
online). These SNPs were located at ZNF184
(rs13195040), HLA-DPA1 and HLA-DPB1 (rs1431403),
CIITA and LOC105371080 (rs6498114), MMEL1
(rs10752747), LOC105375027 (rs10947460),
LOC105369519 (rs10892258), KIAA1109 (rs13119723),
TSBP1 and TSBP1-AS1 (rs9268303), and unknown
genes (rs13030124, rs12527282 and rs9258302).
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